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Objectives
Although antimicrobial agents are used for infections of
the central nervous system (CNS), their pharmacodynam-
ics is commonly evaluated only in commercially available
bacterial growth media. It has been described that differ-
ent media such as cerebrospinal fluid (CSF) may affect the
activity of antibiotics [1,2]. Due to documented penetra-
tion into CSF, cefepime and rifampicin are used for treat-
ment of CNS infections. In the present study, the effects of
CSF on bacterial killing by these agents were investigated.
Methods
CSF was collected from over 150 patients without antibi-
otic therapy. The samples were pooled, stored at -80° and
sterile-filtered before use. Time-kill curves of cefepime
and rifampicin were performed over 24 h using drug con-
centrations of 0.25, 0.5, 1, 2, 4 and 8-fold the respective
MIC for the Staphylococcus aureus ATCC 29213 strain. Kill-
ing curves were performed in Mueller-Hinton broth
(MHB), in CSF incubated in ambient air (CSFair) and in
CSF in air with 5% CO2 (CSFCO2). CO2 was used to adjust
the pH of CSF to physiological values as previously rec-
ommended [3].
Results
Bacterial growth in CSF was slower and less pronounced
than in MHB resulting in bacterial counts that were ~10-
fold lower in CSF than in MHB after overnight incubation.
However, sustained bacterial killing was achieved by
cefepime at lower drug concentrations in CSFCO2 than in
MHB. In contrast, rifampicin concentrations above the
MIC were required to exert sustained killing in CSFCO2.
Both drugs were least effective in CSFair due to the increase
of the pH to 9–10 which is known to reduce the activity of
both agents.
Conclusion
Standard susceptibility tests may lead to over- or underes-
timation of the activity of distinct antibiotics in CSF. Eval-
uation of the antimicrobial activity in pH-adjusted CSF
can provide helpful information on antibiotics consid-
ered for the treatment of bacterial infections residing in
CSF.
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